Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar?
We read with interest the report by Minocha et al [1], in which the authors describe a case of a 17-year-old male with recurrent myocarditis. The second episode began 48 hours after receiving the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine. This occurred 4 months after a previous episode of idiopathic myocarditis.
source https://www.jpeds.com/article/S0022-3476(21)01232-4/fulltext?rss=yes
source https://www.jpeds.com/article/S0022-3476(21)01232-4/fulltext?rss=yes
Comments
Post a Comment